US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Bicara Therapeutics

18.65

-0.0300-0.16%

Volume:105.29K

Turnover:1.98M

Market Cap:1.18B

PE:-8.37

High:19.12

Open:18.57

Low:18.30

Close:18.68

52wk High:20.25

52wk Low:7.80

Shares:63.19M

Float Shares:24.13M

Volume Ratio:0.23

T/O Rate:0.44%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.2271

EPS(LYR):-4.0460

ROE:-26.64%

ROA:-18.59%

PB:2.93

PE(LYR):-4.61

Loading ...

Overview Company News Filings

Bicara Therapeutics publishes data on dual targeting of TGF-β and EGFR with ficerafusp alfa in KRAS/BRAF wild-type MSS colorectal cancer

Bicara Therapeutics Inc. Publishes Study on Molecular Profiling and Spatial Transcriptomics in HNSCC

Bicara Therapeutics’ Innovative Approach to EGFR-Driven Tumors: A Clinical Study Update

Bicara Therapeutics CEO Claire Mazumdar Reports Disposal of Common Shares

Bicara Therapeutics: Strategic Advantages and Favorable Safety Profile Drive Buy Rating

Bicara sinks after J&J reports head and neck cancer data

JonesTrading Keeps Their Buy Rating on Bicara Therapeutics Inc. (BCAX)

Bicara Therapeutics CEO Claire Mazumdar Reports Disposal of Common Shares

Bicara Therapeutics management to meet with Cantor Fitzgerald

BUZZ-U.S. STOCKS ON THE MOVE-Keurig Dr Pepper, Ardelyx, Vertiv

Bicara Shares Rise Premarket on FDA Breakthrough Designation

Bicara Therapeutics Receives FDA Breakthrough Therapy Designation for Ficerafusp Alfa in First-Line HPV-Negative Head and Neck Cancer

Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L Hpv-Negative R/M Hnscc

THOMSON REUTERS

Bicara Therapeutics Chief Medical Officer David Raben Reports Disposal of Common Shares

Bicara Therapeutics CFO Ivan Hyep Reports Disposal of Common Shares

Bicara Therapeutics President and COO Ryan Cohlhepp Reports Disposal of Common Shares

Bicara Therapeutics Files $400 Million Mixed Shelf

MT Newswires Live

BRIEF-Bicara Therapeutics Files For Mixed Shelf Offering Of Up To $400 Million - SEC Filing

Bicara Therapeutics files $400M mixed securities shelf

TD Cowen Keeps Their Buy Rating on Bicara Therapeutics Inc. (BCAX)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BCAX/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BCAX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","market":"US","secType":"STK","nameCN":"Bicara Therapeutics","latestPrice":18.65,"timestamp":1774550434328,"preClose":18.68,"halted":0,"volume":105292,"delay":0,"changeRate":-0.0016059957173448147,"floatShares":24134000,"shares":63193700,"eps":-2.227112,"marketStatus":"Trading","change":-0.03,"latestTime":"03-26 14:40:39 EDT","open":18.57,"high":19.115,"low":18.295,"amount":1980713.7247920001,"amplitude":0.043897,"askPrice":18.67,"askSize":100,"bidPrice":18.59,"bidSize":180,"shortable":3,"etf":0,"ttmEps":-2.227112,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1774555200000},"marketStatusCode":2,"adr":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":18.68,"preHourTrading":{"tag":"盘前","latestPrice":18.61,"preClose":18.68,"latestTime":"08:36 EDT","volume":528,"amount":9807.739392,"timestamp":1774528613938,"change":-0.07,"changeRate":-0.003747,"amplitude":0.261242},"postHourTrading":{"tag":"盘后","latestPrice":18.68,"preClose":18.68,"latestTime":"16:53 EDT","volume":3392,"amount":63362.56,"timestamp":1774471992418,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.234081,"impliedVol":0.4184,"impliedVolPercentile":0.5339},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","floatShares":24134000,"roa":"-18.59%","roe":"-26.64%","lyrEps":-4.045991,"volumeRatio":0.234081,"shares":63193700,"dividePrice":0,"high":19.115,"amplitude":0.043897,"preClose":18.68,"low":18.295,"week52Low":7.8,"pbRate":"2.93","week52High":20.25,"institutionHeld":0,"latestPrice":18.65,"committee":0.285714,"eps":-2.227112,"divideRate":0,"volume":105292,"delay":0,"ttmEps":-2.227112,"open":18.57,"prevYearClose":16.83,"prevWeekClose":18.41,"prevMonthClose":16.78,"prevQuarterClose":16.83,"fiveDayClose":18.79,"twentyDayClose":16.8,"sixtyDayClose":16.51,"earningDate":1774800000000,"earningTime":"盘前"},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BCAX\",params:#limit:5,,,undefined,":[{"date":"2026-03-30","symbol":"BCAX","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2025/12","expectedEps":-0.72,"defaultRemindTime":1774857600000,"name":null,"time":"Pre-Market","dateTimestamp":1774843200000,"actualEps":null},{"market":"US","date":"2025-11-10","symbol":"BCAX","fiscalQuarterEnding":"2025/09","expectedEps":-0.55,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"pre","actualEps":-0.67},{"market":"US","date":"2025-08-12","symbol":"BCAX","fiscalQuarterEnding":"2025/06","expectedEps":-0.54,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"pre","actualEps":-0.5},{"market":"US","date":"2025-05-13","symbol":"BCAX","fiscalQuarterEnding":"2025/03","expectedEps":-0.4,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2025-03-27","symbol":"BCAX","fiscalQuarterEnding":"2024/12","expectedEps":-0.31,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"pre","actualEps":-0.39}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BCAX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BCAX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2857,"buy":0.5,"hold":0.2143,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":14,"updateTime":1770868800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BCAX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BCAX","date":"2026-03-25","current":-8.387544,"percent":0.45288,"low":-22.704836,"twenty":-15.064521,"median":-9.055544,"eighty":-6.584246,"high":-5.144536,"avg":-10.587375,"sd":4.599263,"marketCap":1179804352},"quantilePoints":[{"date":"2024-09-13","current":-12.837909,"twenty":-12.837909,"median":-12.837909,"eighty":-12.837909,"marketCap":832435719},{"date":"2024-09-20","current":-20.633135,"twenty":-21.391361,"median":-20.283845,"eighty":-14.007791,"marketCap":1337893755},{"date":"2024-09-27","current":-21.555755,"twenty":-21.594337,"median":-21.446718,"eighty":-19.006626,"marketCap":1397718272},{"date":"2024-10-04","current":-19.962139,"twenty":-21.575885,"median":-21.337681,"eighty":-19.559541,"marketCap":1294385015},{"date":"2024-10-11","current":-15.936161,"twenty":-21.540658,"median":-20.570229,"eighty":-18.732598,"marketCap":1033332575},{"date":"2024-10-18","current":-17.143955,"twenty":-21.466848,"median":-20.283845,"eighty":-16.808457,"marketCap":1111648307},{"date":"2024-10-25","current":-18.964032,"twenty":-21.403103,"median":-19.23243,"eighty":-16.959431,"marketCap":1229665764},{"date":"2024-10-31","current":-19.878264,"twenty":-21.362844,"median":-19.23243,"eighty":-17.02653,"marketCap":1288946422},{"date":"2024-11-08","current":-19.79439,"twenty":-21.337681,"median":-19.82794,"eighty":-17.143955,"marketCap":1283507830},{"date":"2024-11-15","current":-20.345116,"twenty":-21.127995,"median":-19.949558,"eighty":-18.418848,"marketCap":1210086831},{"date":"2024-11-22","current":-16.257533,"twenty":-21.102833,"median":-19.82794,"eighty":-17.143955,"marketCap":966965549},{"date":"2024-11-29","current":-19.02049,"twenty":-20.975343,"median":-19.458892,"eighty":-17.009755,"marketCap":1131300719},{"date":"2024-12-06","current":-17.876882,"twenty":-20.695202,"median":-19.01323,"eighty":-17.12047,"marketCap":1063281195},{"date":"2024-12-13","current":-16.509127,"twenty":-20.532485,"median":-19.005969,"eighty":-17.12047,"marketCap":981929844},{"date":"2024-12-20","current":-15.187116,"twenty":-20.493904,"median":-18.892739,"eighty":-16.769874,"marketCap":903299275},{"date":"2024-12-27","current":-17.49263,"twenty":-20.458153,"median":-18.854995,"eighty":-16.764842,"marketCap":1040426635},{"date":"2025-01-03","current":-15.484454,"twenty":-20.399979,"median":-18.727694,"eighty":-16.641786,"marketCap":920984351},{"date":"2025-01-10","current":-13.952019,"twenty":-20.332862,"median":-18.565256,"eighty":-16.325863,"marketCap":829838189},{"date":"2025-01-17","current":-10.868852,"twenty":-20.271506,"median":-18.306879,"eighty":-15.951961,"marketCap":646457553},{"date":"2025-01-24","current":-10.951191,"twenty":-20.22215,"median":-18.224539,"eighty":-15.55307,"marketCap":651354959},{"date":"2025-01-31","current":-11.811185,"twenty":-20.138275,"median":-17.666458,"eighty":-14.949245,"marketCap":702505641},{"date":"2025-02-07","current":-11.52757,"twenty":-20.11652,"median":-17.561246,"eighty":-13.156068,"marketCap":685636799},{"date":"2025-02-14","current":-12.003311,"twenty":-19.978914,"median":-17.49263,"eighty":-12.003311,"marketCap":713932921},{"date":"2025-02-21","current":-12.643731,"twenty":-19.965494,"median":-17.085242,"eighty":-11.997822,"marketCap":752023854},{"date":"2025-02-28","current":-11.307997,"twenty":-19.942009,"median":-16.815614,"eighty":-11.891694,"marketCap":672577050},{"date":"2025-03-07","current":-14.409462,"twenty":-19.890007,"median":-16.73236,"eighty":-11.891694,"marketCap":857045999},{"date":"2025-03-14","current":-12.213735,"twenty":-19.838005,"median":-16.60519,"eighty":-11.893524,"marketCap":726448513},{"date":"2025-03-21","current":-11.975864,"twenty":-19.8011,"median":-16.394587,"eighty":-11.882546,"marketCap":712300452},{"date":"2025-03-28","current":-10.745093,"twenty":-19.525992,"median":-16.092853,"eighty":-11.882546,"marketCap":730612568},{"date":"2025-04-04","current":-9.486153,"twenty":-19.364339,"median":-15.936742,"eighty":-11.721526,"marketCap":645010946},{"date":"2025-04-11","current":-8.139007,"twenty":-19.311424,"median":-15.55307,"eighty":-11.500123,"marketCap":553411758},{"date":"2025-04-17","current":-9.430022,"twenty":-19.133936,"median":-15.269456,"eighty":-11.355571,"marketCap":641194313},{"date":"2025-04-25","current":-12.533268,"twenty":-19.02049,"median":-15.045308,"eighty":-11.297018,"marketCap":852199585},{"date":"2025-05-02","current":-11.795546,"twenty":-19.011777,"median":-14.409462,"eighty":-11.329955,"marketCap":802038125},{"date":"2025-05-09","current":-10.531076,"twenty":-18.980807,"median":-14.002338,"eighty":-11.242349,"marketCap":716060542},{"date":"2025-05-16","current":-8.546663,"twenty":-18.933837,"median":-13.265854,"eighty":-11.091295,"marketCap":789139074},{"date":"2025-05-23","current":-9.249533,"twenty":-18.888545,"median":-12.837909,"eighty":-10.95668,"marketCap":854037173},{"date":"2025-05-30","current":-5.575709,"twenty":-18.86506,"median":-12.634583,"eighty":-10.80298,"marketCap":514821897},{"date":"2025-06-06","current":-6.514837,"twenty":-18.854995,"median":-12.506498,"eighty":-10.643069,"marketCap":601534484},{"date":"2025-06-13","current":-6.833787,"twenty":-18.81138,"median":-12.341819,"eighty":-10.421008,"marketCap":630984042},{"date":"2025-06-20","current":-5.569802,"twenty":-18.738652,"median":-12.190862,"eighty":-10.145292,"marketCap":514276535},{"date":"2025-06-27","current":-5.203601,"twenty":-18.705007,"median":-12.094799,"eighty":-9.441248,"marketCap":480464080},{"date":"2025-07-03","current":-5.333543,"twenty":-18.687321,"median":-12.003311,"eighty":-9.12531,"marketCap":492462048},{"date":"2025-07-11","current":-5.859219,"twenty":-18.443191,"median":-11.975864,"eighty":-8.617541,"marketCap":540999282},{"date":"2025-07-18","current":-6.881039,"twenty":-18.418848,"median":-11.920971,"eighty":-8.339475,"marketCap":635346939},{"date":"2025-07-25","current":-7.04642,"twenty":-18.306879,"median":-11.898098,"eighty":-7.625808,"marketCap":650617080},{"date":"2025-08-01","current":-6.562089,"twenty":-18.251986,"median":-11.884376,"eighty":-7.016887,"marketCap":605897381},{"date":"2025-08-08","current":-6.0246,"twenty":-18.224539,"median":-11.847781,"eighty":-6.881039,"marketCap":556269423},{"date":"2025-08-15","current":-6.063601,"twenty":-17.876882,"median":-11.795546,"eighty":-6.786535,"marketCap":622562015},{"date":"2025-08-22","current":-6.180515,"twenty":-17.675607,"median":-11.648291,"eighty":-6.638873,"marketCap":634565840},{"date":"2025-08-29","current":-6.329315,"twenty":-17.657309,"median":-11.619058,"eighty":-6.514837,"marketCap":649843436},{"date":"2025-09-05","current":-6.409029,"twenty":-17.584119,"median":-11.52757,"eighty":-6.407746,"marketCap":658027862},{"date":"2025-09-12","current":-6.366515,"twenty":-17.562161,"median":-11.3858,"eighty":-6.401771,"marketCap":653662835},{"date":"2025-09-19","current":-5.877601,"twenty":-17.506353,"median":-11.36289,"eighty":-6.371769,"marketCap":603465021},{"date":"2025-09-26","current":-5.686286,"twenty":-17.49263,"median":-11.294273,"eighty":-6.328252,"marketCap":583822398},{"date":"2025-10-03","current":-8.880173,"twenty":-17.49263,"median":-11.226216,"eighty":-6.328252,"marketCap":911745073},{"date":"2025-10-10","current":-9.712715,"twenty":-17.21369,"median":-11.089726,"eighty":-6.337818,"marketCap":997223830},{"date":"2025-10-17","current":-9.936118,"twenty":-17.050015,"median":-11.051829,"eighty":-6.344195,"marketCap":1020161070},{"date":"2025-10-24","current":-8.999952,"twenty":-16.959431,"median":-10.928319,"eighty":-6.362264,"marketCap":924043110},{"date":"2025-10-31","current":-8.755273,"twenty":-16.841022,"median":-10.759065,"eighty":-6.371769,"marketCap":898921371},{"date":"2025-11-07","current":-7.749959,"twenty":-16.783048,"median":-10.701761,"eighty":-6.376332,"marketCap":795703789},{"date":"2025-11-14","current":-6.428441,"twenty":-16.754777,"median":-10.617258,"eighty":-6.376332,"marketCap":781190607},{"date":"2025-11-21","current":-7.293982,"twenty":-16.72193,"median":-10.425573,"eighty":-6.385646,"marketCap":886371951},{"date":"2025-11-28","current":-8.366891,"twenty":-16.703998,"median":-10.156917,"eighty":-6.394149,"marketCap":1016752992},{"date":"2025-12-05","current":-8.457052,"twenty":-16.641786,"median":-10.005266,"eighty":-6.400929,"marketCap":1027709382},{"date":"2025-12-12","current":-8.497624,"twenty":-16.572254,"median":-9.798232,"eighty":-6.406463,"marketCap":1032639757},{"date":"2025-12-19","current":-7.952153,"twenty":-16.525595,"median":-9.707395,"eighty":-6.409029,"marketCap":966353598},{"date":"2025-12-26","current":-7.785356,"twenty":-16.417495,"median":-9.581658,"eighty":-6.416794,"marketCap":946084276},{"date":"2026-01-02","current":-7.587003,"twenty":-16.275544,"median":-9.536519,"eighty":-6.433907,"marketCap":921980218},{"date":"2026-01-09","current":-7.465287,"twenty":-16.224597,"median":-9.44371,"eighty":-6.465223,"marketCap":907189092},{"date":"2026-01-16","current":-7.523891,"twenty":-16.076385,"median":-9.207398,"eighty":-6.505387,"marketCap":914310745},{"date":"2026-01-23","current":-7.929613,"twenty":-16.010514,"median":-9.12531,"eighty":-6.514837,"marketCap":963614500},{"date":"2026-01-30","current":-7.623067,"twenty":-15.937323,"median":-9.082399,"eighty":-6.531258,"marketCap":926362774},{"date":"2026-02-06","current":-6.807115,"twenty":-15.936161,"median":-9.042505,"eighty":-6.562089,"marketCap":827207445},{"date":"2026-02-13","current":-6.338281,"twenty":-15.928174,"median":-8.933537,"eighty":-6.562089,"marketCap":770234217},{"date":"2026-02-20","current":-6.951372,"twenty":-15.628091,"median":-8.853601,"eighty":-6.527974,"marketCap":844737669},{"date":"2026-02-27","current":-8.759817,"twenty":-15.498177,"median":-8.759817,"eighty":-6.531952,"marketCap":1064501760},{"date":"2026-03-06","current":-9.890416,"twenty":-15.312456,"median":-8.853601,"eighty":-6.556096,"marketCap":1201893200},{"date":"2026-03-13","current":-10.269994,"twenty":-15.203584,"median":-8.927397,"eighty":-6.566815,"marketCap":1248019912},{"date":"2026-03-20","current":-10.045455,"twenty":-15.15052,"median":-9.021228,"eighty":-6.577062,"marketCap":1220733688},{"date":"2026-03-25","current":-9.708646,"twenty":-15.064521,"median":-9.055544,"eighty":-6.584246,"marketCap":1179804352}],"updateTime":1774515843159},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BCAX\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2581464863","title":"Bicara Therapeutics publishes data on dual targeting of TGF-β and EGFR with ficerafusp alfa in KRAS/BRAF wild-type MSS colorectal cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2581464863","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581464863?lang=en_us&edition=fundamental","pubTime":"2025-11-08 23:10","pubTimestamp":1762614656,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics publishes data on dual targeting of TGF-β and EGFR with ficerafusp alfa in KRAS/BRAF wild-type MSS colorectal cancer. Bicara Therapeutics Inc. published a document detailing research on dual targeting of TGF-β and EGFR in KRAS/BRAF wild-type MSS colorectal cancer cell lines. The document compares the antitumor activity of ficerafusp alfa with cetuximab and includes data on immune cell activity and tumor cytotoxicity. The full document can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief on November 08, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251108:nNDL6VpBV0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2581776234","title":"Bicara Therapeutics Inc. Publishes Study on Molecular Profiling and Spatial Transcriptomics in HNSCC","url":"https://stock-news.laohu8.com/highlight/detail?id=2581776234","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581776234?lang=en_us&edition=fundamental","pubTime":"2025-11-05 22:43","pubTimestamp":1762353782,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief on November 05, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL42rx8J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861558580.USD","LU1861559042.SGD","BK4548","BK4588","BK4585","TXG","BCAX","BK4139","BK4121"],"gpt_icon":0},{"id":"2578678982","title":"Bicara Therapeutics’ Innovative Approach to EGFR-Driven Tumors: A Clinical Study Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2578678982","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578678982?lang=en_us&edition=fundamental","pubTime":"2025-10-28 03:53","pubTimestamp":1761594792,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics Inc. (($BCAX)) announced an update on their ongoing clinical study. Study Overview: Bicara Therapeutics Inc. is conducting a cl...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bicara-therapeutics-innovative-approach-to-egfr-driven-tumors-a-clinical-study-update?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bicara-therapeutics-innovative-approach-to-egfr-driven-tumors-a-clinical-study-update?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2577989406","title":"Bicara Therapeutics CEO Claire Mazumdar Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2577989406","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577989406?lang=en_us&edition=fundamental","pubTime":"2025-10-21 07:10","pubTimestamp":1761001807,"startTime":"0","endTime":"0","summary":"Claire Mazumdar, Chief Executive Officer and Director of Bicara Therapeutics Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 20, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDLcZ2Sz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2577589500","title":"Bicara Therapeutics: Strategic Advantages and Favorable Safety Profile Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2577589500","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577589500?lang=en_us&edition=fundamental","pubTime":"2025-10-21 04:55","pubTimestamp":1760993717,"startTime":"0","endTime":"0","summary":"Analyst Soumit Roy from JonesTrading reiterated a Buy rating on Bicara Therapeutics Inc. and keeping the price target at $27.00. Soumit Roy’s ratin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/bicara-therapeutics-strategic-advantages-and-favorable-safety-profile-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/bicara-therapeutics-strategic-advantages-and-favorable-safety-profile-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX"],"gpt_icon":0},{"id":"2577099861","title":"Bicara sinks after J&J reports head and neck cancer data","url":"https://stock-news.laohu8.com/highlight/detail?id=2577099861","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577099861?lang=en_us&edition=fundamental","pubTime":"2025-10-21 00:45","pubTimestamp":1760978711,"startTime":"0","endTime":"0","summary":"Shares of Bicara Therapeutics (BCAX) (BCRX) after moving lower after Johnson & Johnson (JNJ) reported Phase 1b/2 data for amivantamab in patients w...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bicara-sinks-after-jj-reports-head-and-neck-cancer-data-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bicara-sinks-after-jj-reports-head-and-neck-cancer-data-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BVYPNV92.GBP","IE0002270589.USD","BCRX","SG9999002224.SGD","LU0289739699.SGD","IE00B3T34201.USD","LU0466842654.USD","LU2112291526.USD","LU2750360997.AUD","LU1244550221.USD","IE00B19Z3581.USD","LU1066053197.SGD","IE00B19Z3B42.SGD","LU2129689514.USD","LU1894683264.USD","LU1935042991.SGD","LU0203347892.USD","LU1221951046.USD","LU2430703251.USD","LU2471134879.HKD","IE00BSNM7G36.USD","LU2468319806.SGD","IE00BJJMRZ35.SGD","LU0122379950.USD","BK4568","LU0234572021.USD","LU0432979614.USD","LU2471134796.USD","LU2750360641.GBP","JNJ","LU0320765646.SGD","BK4585","IE00BFTCPJ56.SGD","LU1496350502.SGD","LU0795875169.SGD","LU1585245621.USD","LU2592432038.USD","LU2505996509.AUD","LU1066051811.HKD","IE00BLSP4239.USD","IE00BVYPNW00.USD","BCAX","LU1674673691.USD","LU0795875086.SGD","LU1732800096.USD","BK4532","LU1059921491.USD","LU2129689605.HKD","LU1280957306.USD","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2576320190","title":"JonesTrading Keeps Their Buy Rating on Bicara Therapeutics Inc. (BCAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2576320190","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576320190?lang=en_us&edition=fundamental","pubTime":"2025-10-17 19:55","pubTimestamp":1760702128,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Soumit Roy from JonesTrading reiterated a Buy rating on Bicara Therapeutics Inc., with a price target of $27.00. Th...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jonestrading-keeps-their-buy-rating-on-bicara-therapeutics-inc-bcax-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jonestrading-keeps-their-buy-rating-on-bicara-therapeutics-inc-bcax-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX"],"gpt_icon":0},{"id":"2575752045","title":"Bicara Therapeutics CEO Claire Mazumdar Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2575752045","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575752045?lang=en_us&edition=fundamental","pubTime":"2025-10-16 06:01","pubTimestamp":1760565661,"startTime":"0","endTime":"0","summary":"Claire Mazumdar, Chief Executive Officer of Bicara Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 15, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nNDL5qCVwq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2575787153","title":"Bicara Therapeutics management to meet with Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2575787153","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575787153?lang=en_us&edition=fundamental","pubTime":"2025-10-15 20:56","pubTimestamp":1760532969,"startTime":"0","endTime":"0","summary":"Meetings to be held in London on October 14 and in Zurich on October 15 hosted by Cantor Fitzgerald. Published first on TheFly – the ultimate sourc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-management-to-meet-with-cantor-fitzgerald-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-management-to-meet-with-cantor-fitzgerald-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2575281804","title":"BUZZ-U.S. STOCKS ON THE MOVE-Keurig Dr Pepper, Ardelyx, Vertiv","url":"https://stock-news.laohu8.com/highlight/detail?id=2575281804","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575281804?lang=en_us&edition=fundamental","pubTime":"2025-10-14 01:46","pubTimestamp":1760377569,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Keurig Dr Pepper, Ardelyx, VertivEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nL6N3VU0HC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRRK","KDP","PGEN","CERO","DVN","STX","BK4567","MACW.SI","CVX","JEF","LNT","TVRD","BK4155","VRT","NDRA","LU0496367417.USD","LU0878866978.SGD","RNA","SG9999014542.SGD","FAST","LU1571399168.USD","ABEO","ALK","BK4566","TGT","MKSI","COP","ARDX","NPO","AGX","NEM","LU2054465674.USD","XOM","BCAX","SCCO","STUB","BK4500"],"gpt_icon":1},{"id":"2575405295","title":"Bicara Shares Rise Premarket on FDA Breakthrough Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2575405295","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575405295?lang=en_us&edition=fundamental","pubTime":"2025-10-13 20:04","pubTimestamp":1760357040,"startTime":"0","endTime":"0","summary":"Shares of Bicara Therapeutics rose sharply in premarket trading Monday after the clinical-stage biopharmaceutical company won U.S. Food and Drug Administration breakthrough-therapy designation for its lead program, ficerafusp alfa, in certain head and neck cancers.Bicara on Monday said the designation covers ficerafusp alfa in combination with Merck's blockbuster cancer drug Keytruda for first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma that is human papillomavirus-negative.The Boston company said HPV-negative head-and-neck squamous cell carcinoma has particularly poor outcomes and limited therapeutic options.The FDA's breakthrough-therapy designation aims to expedite the development and review of a drug for serious conditions when preliminary clinical evidence shows the drug might offer substantial improvement over available therapies.Bicara shares, which closed Friday at $17.78, were recently up 40% to $24.98 in pre","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234572021.USD","LU0070302665.USD","LU0965508806.USD","LU0266013472.USD","LU1974910355.USD","BK4534","IE00BFTCPJ56.SGD","LU1941712264.USD","LU0238689110.USD","IE00BJT1NW94.SGD","IE0009355771.USD","LU1934455194.USD","IE0002141913.USD","LU0006306889.USD","LU0265550946.USD","LU1699723380.USD","LU2324357040.USD","LU1989772840.SGD","SG9999002232.USD","LU0211331839.USD","LU1069347547.HKD","LU0320765489.SGD","LU1093756168.USD","LU1941712348.USD","IE00B4R5TH58.HKD","SG9999014559.SGD","LU1116320737.USD","LU1066051225.USD","SG9999014567.USD","LU0208291251.USD","BK4588","BCAX","LU2361045086.USD","IE00BLSP4452.SGD","LU1585245621.USD","LU1430594728.SGD","LU2023250843.SGD","LU1917777945.USD","SG9999001176.SGD","MRK","IE00B2B36J28.USD","LU0265550359.USD","LU0965509101.SGD","SG9999014575.USD","LU1023059063.AUD","LU1061106388.HKD","LU1093756325.SGD","LU0106261372.USD","LU0203345920.USD","SG9999015341.SGD"],"gpt_icon":0},{"id":"2575354403","title":"Bicara Therapeutics Receives FDA Breakthrough Therapy Designation for Ficerafusp Alfa in First-Line HPV-Negative Head and Neck Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2575354403","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575354403?lang=en_us&edition=fundamental","pubTime":"2025-10-13 19:31","pubTimestamp":1760355073,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics Receives FDA Breakthrough Therapy Designation for Ficerafusp Alfa in First-Line HPV-Negative Head and Neck Cancer. Bicara Therapeutics Inc. announced that the U.S. Food and Drug Administration  has granted Breakthrough Therapy Designation  to ficerafusp alfa in combination with pembrolizumab for the first-line treatment of patients with metastatic or unresectable, recurrent head and neck squamous cell carcinoma  whose tumors express PD-L1 , excluding HPV-positive oropharyngeal squamous cell carcinoma. The designation is based on promising results from multiple Phase 1/1b cohorts, which demonstrated significant clinical benefit and a favorable safety profile. This regulatory milestone is intended to expedite the development and review of ficerafusp alfa, highlighting its potential to address an urgent unmet need in HPV-negative HNSCC. The grant was announced solely by Bicara Therapeutics Inc.Disclaimer: This news brief was created by Public Technologies  using genera","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nNDL6ZTwR1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210149790.SGD","IE00B3QW5Z07.USD","BK4588","BCAX","LU0314104364.USD","LU2095319765.USD","LU2210150020.SGD","BK4585","IE00B64PRP62.GBP","NDAQ","IE00BGHQF748.EUR","BK4139","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2575403887","title":"Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L Hpv-Negative R/M Hnscc","url":"https://stock-news.laohu8.com/highlight/detail?id=2575403887","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575403887?lang=en_us&edition=fundamental","pubTime":"2025-10-13 19:30","pubTimestamp":1760355058,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nTUA1QFSQ0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2574488627","title":"Bicara Therapeutics Chief Medical Officer David Raben Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2574488627","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574488627?lang=en_us&edition=fundamental","pubTime":"2025-10-11 05:23","pubTimestamp":1760131430,"startTime":"0","endTime":"0","summary":"David Raben, Chief Medical Officer of Bicara Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 10, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nNDL9lhf9Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2574620488","title":"Bicara Therapeutics CFO Ivan Hyep Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2574620488","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574620488?lang=en_us&edition=fundamental","pubTime":"2025-10-11 05:23","pubTimestamp":1760131414,"startTime":"0","endTime":"0","summary":"Ivan Hyep, Chief Financial Officer of Bicara Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 10, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nNDL28hsmK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2574908936","title":"Bicara Therapeutics President and COO Ryan Cohlhepp Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2574908936","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574908936?lang=en_us&edition=fundamental","pubTime":"2025-10-09 05:34","pubTimestamp":1759959248,"startTime":"0","endTime":"0","summary":"Ryan Cohlhepp, President and COO of Bicara Therapeutics Inc., reported a disposal of common shares of Bicara Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 08, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nNDL110XCF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2572351596","title":"Bicara Therapeutics Files $400 Million Mixed Shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2572351596","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572351596?lang=en_us&edition=fundamental","pubTime":"2025-10-04 04:53","pubTimestamp":1759524790,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics  on Friday filed a registration statement with the US Securities and Exchange Commission to issue up to $400 million of securities.The filing also includes a sales-agreement prospectus to sell up to $150 million of common stock under an at-the-market arrangement with TD Securities, the company said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2572635800","title":"BRIEF-Bicara Therapeutics Files For Mixed Shelf Offering Of Up To $400 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2572635800","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572635800?lang=en_us&edition=fundamental","pubTime":"2025-10-04 04:37","pubTimestamp":1759523864,"startTime":"0","endTime":"0","summary":"BRIEF-Bicara Therapeutics Files For Mixed Shelf Offering Of Up To $400 Million - SEC FilingOct 3  - Bicara Therapeutics Inc BCAX.O:BICARA THERAPEUTICS INC : FILES FOR MIXED SHELF OFFERING OF UP TO $400 MILLION - SEC FILINGSource text: [ID:n0001193125-25-230307]Further company coverage: BCAX.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251003:nFWN3VK0SR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2572635528","title":"Bicara Therapeutics files $400M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2572635528","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572635528?lang=en_us&edition=fundamental","pubTime":"2025-10-04 04:35","pubTimestamp":1759523706,"startTime":"0","endTime":"0","summary":"16:34 EDT Bicara Therapeutics (BCAX) files $400M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-movin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-files-400m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-files-400m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2572514993","title":"TD Cowen Keeps Their Buy Rating on Bicara Therapeutics Inc. (BCAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2572514993","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572514993?lang=en_us&edition=fundamental","pubTime":"2025-10-02 19:55","pubTimestamp":1759406115,"startTime":"0","endTime":"0","summary":"In a report released on September 30, Tyler Van Buren from TD Cowen maintained a Buy rating on Bicara Therapeutics Inc.. The company’s shares close...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-keeps-their-buy-rating-on-bicara-therapeutics-inc-bcax-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-keeps-their-buy-rating-on-bicara-therapeutics-inc-bcax-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["COWN","TD","BCAX"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":5,"totalSize":104,"code":"91000000","status":"200"}]}}